Aliases & Classifications for Skin Atrophy

MalaCards integrated aliases for Skin Atrophy:

Name: Skin Atrophy 12 15
Atrophic Condition of Skin 12 73
Atrophoderma 12 76
Atrophy - Skin 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2733
ICD10 33 L90 L90.9
NCIt 50 C35163
UMLS 73 C0151514

Summaries for Skin Atrophy

MalaCards based summary : Skin Atrophy, also known as atrophic condition of skin, is related to kindler syndrome and atrophoderma vermiculata. An important gene associated with Skin Atrophy is FERMT1 (Fermitin Family Member 1), and among its related pathways/superpathways are Bladder cancer and Adhesion. The drugs Tacrolimus and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related phenotypes are growth/size/body region and immune system

Wikipedia : 76 Atrophoderma refers to conditions involving skin... more...

Related Diseases for Skin Atrophy

Graphical network of the top 20 diseases related to Skin Atrophy:



Diseases related to Skin Atrophy

Symptoms & Phenotypes for Skin Atrophy

MGI Mouse Phenotypes related to Skin Atrophy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.97 CD44 EBP FERMT1 GJA1 HBEGF KL
2 immune system MP:0005387 9.87 FBLIM1 FERMT1 GJA1 KL MMP1 MYSM1
3 integument MP:0010771 9.8 CD44 EBP FERMT1 GJA1 HBEGF KL
4 respiratory system MP:0005388 9.55 CD44 GJA1 HBEGF KL TCOF1
5 skeleton MP:0005390 9.5 CD44 FBLIM1 GJA1 HBEGF KL MYSM1
6 vision/eye MP:0005391 9.02 CD44 GJA1 KL MYSM1 TCOF1

Drugs & Therapeutics for Skin Atrophy

Drugs for Skin Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
2
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Fluticasone Approved, Experimental, Investigational Phase 4 90566-53-3 62924
5
Racepinephrine Approved Phase 4 329-65-7 838
6
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
7
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
8
Hydroquinone Approved, Investigational Phase 4 123-31-9 785
9
Clobetasol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 25122-46-7, 25122-41-2 32798 5311051
10
Betamethasone Approved, Vet_approved Phase 4,Phase 1 378-44-9 9782
11
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
12
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Not Applicable 302-79-4 5538 444795
13
Calcitriol Approved, Nutraceutical Phase 4,Phase 3 32222-06-3 134070 5280453
14 Anti-Allergic Agents Phase 4
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Not Applicable
16 Calcineurin Inhibitors Phase 4
17 Dermatologic Agents Phase 4,Phase 1,Not Applicable
18 Immunosuppressive Agents Phase 4,Phase 1,Phase 2,Not Applicable
19 mometasone furoate Phase 4
20 Peripheral Nervous System Agents Phase 4,Not Applicable
21 glucocorticoids Phase 4,Phase 3,Phase 1,Not Applicable
22 Hormone Antagonists Phase 4,Phase 3,Phase 1,Not Applicable
23 Hormones Phase 4,Phase 3,Phase 1,Not Applicable
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Not Applicable
25 triamcinolone acetonide Phase 4,Not Applicable
26 Triamcinolone diacetate Phase 4,Not Applicable
27 Triamcinolone hexacetonide Phase 4,Not Applicable
28 Anti-Asthmatic Agents Phase 4,Phase 1
29 Autonomic Agents Phase 4
30 Bronchodilator Agents Phase 4
31 Epinephryl borate Phase 4
32 Respiratory System Agents Phase 4,Phase 1
33 Analgesics Phase 4
34 Analgesics, Non-Narcotic Phase 4
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4
36 Antirheumatic Agents Phase 4
37 Antioxidants Phase 4
38 Keratolytic Agents Phase 4,Not Applicable
39 Protective Agents Phase 4
40 Radiation-Protective Agents Phase 4
41 EMLA Phase 4
42 Emollients Phase 4,Phase 1
43 Antihypertensive Agents Phase 4
44 Betamethasone benzoate Phase 4,Phase 1
45 Betamethasone sodium phosphate Phase 4,Phase 1
46 Betamethasone Valerate Phase 4,Phase 1 2152-44-5
47 Betamethasone-17,21-dipropionate Phase 4,Phase 1
48 Bone Density Conservation Agents Phase 4,Phase 3
49 Calcium, Dietary Phase 4,Phase 3
50 Micronutrients Phase 4,Phase 3

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
2 Cutivate Lotion HPA Axis Pediatric Study Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
3 Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
4 Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma Completed NCT00469183 Phase 4 Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
5 Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
6 Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis Completed NCT01202149 Phase 4
7 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
8 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients Completed NCT00121316 Phase 4 Pimecrolimus;Placebo
9 Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis Completed NCT00733954 Phase 4 clobetasol propionate spray;clobetasol propionate ointment
10 Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis Completed NCT00988637 Phase 4 Vectical™ Ointment weekdays and Clobex® Spray weekends regimen;Clobex® Spray morning and Vectical™ Ointment evening regimen
11 Efficacy of Topical Coal Tar in Children With Atopic Dermatitis Recruiting NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
12 Intralesional Steroids in the Treatment of Alopecia Areata Recruiting NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
13 Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis Completed NCT00658788 Phase 3 clobetasol propionate spray 0.05%;calcitriol ointment
14 Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis Recruiting NCT02749656 Phase 3 0.25% Desoximetasone cream (Topoxy®);0.25% Desoximetasone cream (Topicorte®);Placebo
15 A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26) Recruiting NCT02608476 Phase 3 CB-03-01 cream, 1%;Vehicle cream
16 A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25) Recruiting NCT02608450 Phase 3 CB-03-01 cream, 1%;Vehicle cream
17 A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 Unknown status NCT01670513 Phase 1, Phase 2 IDP-118 Low Strength;IDP-118 High Strength
18 Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test Completed NCT02111499 Phase 1, Phase 2 LAS41004-IMP1;LAS41004 IMP2;LAS41004 IMP3;LAS41004 IMP4;LAS41004 IMP6;LAS41004 IMP5
19 Novel Compositions for Treating or Preventing Dermal Disorders Recruiting NCT03103893 Phase 1, Phase 2 Rapamycin
20 A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin Completed NCT02355639 Phase 1 Clobetasol propionate 0.05 % ointment;Betamethasone dipropionate 0.064 % ointment;Petrolatum ointment
21 A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin Completed NCT02392130 Phase 1 Clobetasol propionate 0.05% ointment;LEO 130852A gel 1%;LEO 130852A placebo gel
22 A Study Assessing GW870086's Potential to Cause Skin Thinning Completed NCT01381445 Phase 1 GW870086 0.2%;GW870086 2%;Clobetasol Propionate;Placebo
23 Olaparib and Radiotherapy in Head and Neck Cancer Recruiting NCT02229656 Phase 1 Olaparib
24 The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata Unknown status NCT00999869 Not Applicable Botulinum toxin type A;Triamcinolone acetonide
25 Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging Completed NCT00974480 Not Applicable Tretinoin (Rejuva-A)
26 Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser Completed NCT02416531 Not Applicable Clobetasol propionate
27 Nonneoplastic Epithelial Disorders of Vulva and High Intensity Focused Ultrasound Recruiting NCT02890277 Not Applicable Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).

Search NIH Clinical Center for Skin Atrophy

Genetic Tests for Skin Atrophy

Anatomical Context for Skin Atrophy

MalaCards organs/tissues related to Skin Atrophy:

41
Skin, Testes, Bone, Thyroid, Tongue

Publications for Skin Atrophy

Articles related to Skin Atrophy:

(show top 50) (show all 51)
# Title Authors Year
1
Mineralocorticoid receptor blockade improves glucocorticoid-induced skin atrophy but partially ameliorates anti-inflammatory actions in an irritative model in human skin explants. ( 29178328 )
2018
2
Annular Plaques With Skin Atrophy in a Young Patient. ( 28122082 )
2017
3
Intralesional Treatment With 5-Fluorouracil and Steroid Improves Allergic Contact Dermatitis Without Causing Skin Atrophy and Rebound Lesions. ( 28338541 )
2017
4
Surgical Answer to Intralesional Steroid-Induced Skin Atrophy. ( 27870650 )
2016
5
Resveratrol Derivative-Rich Melinjo Seed Extract Attenuates Skin Atrophy in Sod1-Deficient Mice. ( 26180586 )
2015
6
Acral skin atrophy in an infant: an early clue to Kindler syndrome diagnosis. ( 25764106 )
2015
7
Topical corticosteroid-induced skin atrophy: a comprehensive review. ( 25862024 )
2015
8
Palladium and Platinum Nanoparticles Attenuate Aging-Like Skin Atrophy via Antioxidant Activity in Mice. ( 25333617 )
2014
9
Validation of Dermaphot(Ar) for the assessment of steroid-induced skin atrophy. ( 24488534 )
2014
10
Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. ( 25027750 )
2014
11
Collagen peptide and vitamin C additively attenuate age-related skin atrophy in Sod1-deficient mice. ( 25229861 )
2014
12
Hyalurosome gene regulation and dose-dependent restoration of skin atrophy by retinaldehyde and defined-size hyaluronate fragments in dermatoporosis. ( 25138066 )
2014
13
Validation of Dermaphot(Ar) for the assessment of steroid-induced skin atrophy. ( 23242470 )
2013
14
Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. ( 22512680 )
2012
15
Vulvar skin atrophy induced by topical glucocorticoids. ( 22594868 )
2012
16
Fluorescence spectroscopy as a tool to detect and evaluate glucocorticoid-induced skin atrophy. ( 22249456 )
2012
17
Linear skin atrophy preceding calcinosis cutis in pseudo-pseudohypoparathyroidism. ( 22299648 )
2012
18
Shortened treatment duration of glucocorticoid-induced skin atrophy in rats. ( 21824195 )
2011
19
Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. ( 22110776 )
2011
20
Evaluation of skin atrophy associated with linear atrophoderma of Moulin by ultrasound imaging. ( 21679833 )
2011
21
Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy. ( 20051715 )
2010
22
A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. ( 19755910 )
2009
23
Skin atrophy in cytoplasmic SOD-deficient mice and its complete recovery using a vitamin C derivative. ( 19289104 )
2009
24
Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. ( 19057668 )
2008
25
In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle. ( 18246695 )
2008
26
Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans. ( 17123343 )
2006
27
Glucocorticoid therapy-induced skin atrophy. ( 16689857 )
2006
28
Skin atrophy caused by thiocolchicoside injections. ( 17184273 )
2006
29
Action of topical thyroid hormone analogues on glucocorticoid-induced skin atrophy in mice. ( 16571090 )
2006
30
Hyaluronate fragments reverse skin atrophy by a CD44-dependent mechanism. ( 17177600 )
2006
31
Dose-response effects of tri-iodothyroacetic acid (Triac) and other thyroid hormone analogues on glucocorticoid-induced skin atrophy in the haired mouse. ( 12353707 )
2002
32
Topical tacrolimus and pimecrolimus are not associated with skin atrophy. ( 11903264 )
2002
33
Eyelid skin atrophy associated with chronic usage of ophthalmic steroid ointment, and its successful treatment with the Versapulse laser. ( 11702982 )
2001
34
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. ( 11260007 )
2001
35
Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. ( 9553910 )
1998
36
The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. ( 9990383 )
1998
37
Skin atrophy of the eyelid induced by topical ophthalmic corticosteroids. ( 9686858 )
1998
38
Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. ( 7894098 )
1995
39
In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin. ( 8106754 )
1994
40
Combination of a dual 5-lipoxygenase/cyclooxygenase inhibitor with a glucocorticoid results in synergistic topical antiinflammatory activity without inducing skin atrophy. ( 8225561 )
1993
41
Morphometric computerized analysis as a method to assess skin atrophy caused by corticosteroids. ( 8489771 )
1993
42
0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. ( 1618247 )
1992
43
Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. ( 2768567 )
1989
44
Remote skin atrophy caused by topical steroids. ( 21253139 )
1988
45
Infection and prematurity as the cause of linear skin atrophy, alopecia, anonychia, and tongue lesions? ( 3901928 )
1985
46
Linear skin atrophy, scarring alopecia, anonychia, and tongue lesion: a "new" syndrome? ( 4040704 )
1985
47
Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo. ( 3888708 )
1985
48
A study of potential skin atrophy following topical application of weak corticosteroids. ( 7261664 )
1981
49
Comparative evaluation of skin atrophy in man induced by topical corticoids. ( 154921 )
1979
50
Periarticular perilymphatic skin atrophy after intra-articular corticosteroid injections. ( 671670 )
1978

Variations for Skin Atrophy

Expression for Skin Atrophy

Search GEO for disease gene expression data for Skin Atrophy.

Pathways for Skin Atrophy

Pathways related to Skin Atrophy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.23 HBEGF MMP1
2 11.22 CD44 FERMT1 GJA1
3 11.03 CD44 MMP1
4 10.85 CD44 MMP1
5 10.69 GJA1 MMP1
6 10.58 CD44 HBEGF MMP1

GO Terms for Skin Atrophy

Cellular components related to Skin Atrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.35 CD44 EBP GJA1 HBEGF KL
2 apical plasma membrane GO:0016324 9.33 CD44 GJA1 KL
3 focal adhesion GO:0005925 8.92 CD44 FBLIM1 FERMT1 GJA1

Biological processes related to Skin Atrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of heart contraction GO:0008016 8.62 GJA1 HBEGF

Molecular functions related to Skin Atrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.96 HBEGF KL
2 scaffold protein binding GO:0097110 8.62 GJA1 TCOF1

Sources for Skin Atrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....